Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors#China#Hong_Kong#Akeso#bispecific_ADC#AK158D1
Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors
Akeso Inc. announces that its bispecific antibody-drug conjugate AK158D1 has gained Phase I clearance in China for treating advanced tumors.
third-news.com
September 17, 2026 at 6:42 AM
Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors#China#Hong_Kong#Akeso#bispecific_ADC#AK158D1